Welcome to our dedicated page for TenX Keane Acquisition Ordinary Share news (Ticker: TENK), a resource for investors and traders seeking the latest updates and insights on TenX Keane Acquisition Ordinary Share stock.
TenX Keane Acquisition (TENK) is a special purpose acquisition company (SPAC) focused on enabling strategic mergers in the biotechnology and healthcare sectors. This dedicated news hub provides investors and industry professionals with essential updates on TENK's merger activities, regulatory developments, and market positioning.
Our curated collection features official press releases, SEC filings, and verified news about potential business combinations. Users can track critical updates including merger target evaluations, shareholder meeting outcomes, and post-merger integration progress. The resource prioritizes timely disclosure of material events while maintaining strict editorial neutrality.
Key content categories include merger announcements, leadership changes, financial reporting updates, and partnership developments. All information is sourced directly from regulatory filings and company communications to ensure accuracy. Bookmark this page for streamlined access to TENK's evolving strategic initiatives in oncology-focused biotech ventures and other high-potential healthcare sectors.
Citius Pharmaceuticals (CTXR) has completed the merger of its oncology subsidiary with TenX Keane Acquisition, forming Citius Oncology, Inc. The new entity is set to trade on Nasdaq under the ticker CTOR starting August 13, 2024. Citius Pharma retains approximately 90% ownership of Citius Oncology.
Key highlights include:
- FDA approval of LYMPHIR™ for treating cutaneous T-cell lymphoma
- Plans to distribute a portion of Citius Oncology shares to Citius Pharma shareholders
- Citius Pharma's Mino-Lok antibiotic lock solution achieved primary and secondary endpoints in Phase 3 Trial
The merger aims to provide greater financial and strategic flexibility, potentially unlocking value for both companies.
TenX Keane Acquisition (Nasdaq: TENKU) faced a trading halt on August 7, 2024, due to additional information requested by Nasdaq following unusual trading activity. The company is working with Nasdaq to lift the halt. Meanwhile, TenX shareholders approved the merger with Citius Oncology on August 2, 2024. The post-merger entity is expected to trade as Citius Oncology, Inc. (CTOR) on Nasdaq.
In a related development, Citius Pharmaceuticals (Nasdaq: CTXR) announced FDA approval for LYMPHIR™, a treatment for relapsed or refractory cutaneous T-cell lymphoma. TenX and Citius Pharma are progressing towards closing the business combination in the near future.
TenX Keane Acquisition shareholders have approved the merger with Citius Pharmaceuticals' oncology subsidiary to form Citius Oncology, Inc. The vote took place at an extraordinary general meeting on August 2, 2024. The newly combined company is expected to trade on Nasdaq under the Citius Oncology name. This merger aims to support the commercialization of LYMPHIR, pending approval, and explore additional oncology assets. The transaction is anticipated to provide Citius Oncology with improved access to public equity markets. Subject to closing conditions, the merger is expected to be completed in the coming weeks. This strategic move positions Citius Oncology to advance its oncology pipeline and potentially strengthen its market presence in the biopharmaceutical sector.
Citius Pharmaceuticals (Nasdaq: CTXR) announced that shareholders of TenX Keane Acquisition (Nasdaq: TENK) have approved the merger with Citius Pharma's oncology subsidiary. The newly combined public company will be renamed Citius Oncology, Inc. and continue trading on Nasdaq. Key points:
- Citius Pharma to receive 65.6 million shares of TenX Keane
- Citius Pharma to retain approximately 90% majority control post-transaction
- Transaction expected to support commercialization of LYMPHIR, if approved
- Merger to provide improved access to public equity markets
- Positions company to explore additional targeted oncology opportunities
The merger is expected to be completed in the coming weeks, subject to customary closing conditions. Leonard Mazur, Chairman and CEO of Citius Pharma, expressed optimism about unlocking and growing the value of their oncology asset.
Citius Pharmaceuticals (Nasdaq: CTXR), a biopharma company, has outlined key milestones for the second half of 2024, hinging on two late-stage candidates: Mino-Lok® and LYMPHIR™. Mino-Lok® has shown positive Phase 3 results for catheter-related bloodstream infections (CRBSIs) and awaits FDA submission and a Type B meeting. LYMPHIR™, an IL-2-based immunotherapy for cutaneous T-cell lymphoma (CTCL), is under FDA review with a decision expected by August 13, 2024. If approved, Citius aims for commercialization in 2024, potentially benefiting from 12 years of exclusivity. The company is also advancing Halo-Lido, a topical treatment for hemorrhoids, and has secured $15 million to strengthen its financial position. Additionally, Citius plans to merge a subsidiary with TenX Keane Acquisition (Nasdaq: TENK) to form Citius Oncology, Inc., pending regulatory approval.
Citius Pharmaceuticals (CTXR) reported its fiscal Q2 2024 financial results and provided a business update. Key highlights include:
- The FDA accepted LYMPHIR's BLA with a PDUFA target date of Aug 13, 2024.
- Topline results for Mino-Lok’s Phase 3 trial expected in Q2 2024.
- Continued engagement with FDA for Halo-Lido’s development.
- Merger with TenX Keane Acquisition progressing, awaiting SEC and TENK shareholder approval.
- Completed a $15M direct offering in April 2024, extending cash runway to Dec 2024.
Financial highlights:
- $12.6M in cash as of Mar 31, 2024.
- R&D expenses decreased to $3.6M from $4.7M YoY; G&A expenses slightly decreased to $4.3M from $4.8M YoY.
- Net loss improved to $8.5M, $0.05 per share, from $10.5M, $0.07 per share YoY.
FAQ
What is the current stock price of TenX Keane Acquisition Ordinary Share (TENK)?
What is the market cap of TenX Keane Acquisition Ordinary Share (TENK)?
